Vijayakrishna Gadi, MD, PhD, discusses factors to consider in the first- and second-line management of HER2+ mBC with particular emphasis on treatment selection, safety, and sequencing.
The Evolving Paradigm in the Treatment of HER2 Positive Metastatic Breast Cancer
An expert oncologist reviews key considerations in selecting and sequencing treatment appropriately in patients with HER2+ breast cancer and CNS metastases, including challenges associated with treating leptomeningeal disease.
EP. 3: Role of Multidisciplinary Team in the Management of Patients with HER2+ BC and CNS Metastases
Highlighting the importance of a multidisciplinary approach to care in HER2+ mBC, Vijayakrishna Gadi, MD, PhD, describes the value of effective consultation with neurooncologists and radiation oncologists for CNS metastases.
A leader in breast medical oncology reflects on key clinical trial updates presented at the 2022 ASCO Annual Meeting, and their implications for clinical practice.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5